Psyence Biomedical Ltd. (PBMWW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Psyence Biomedical Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 257,209 | $6,481.36 | $7,716.27 | $1,234.91 | 19.05% |
Psyence Biomedical Ltd. (PBMWW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Psyence Biomedical Ltd. ever had a stock split?
Psyence Biomedical Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Jody Aufrichtig CEO | NASDAQ (CM) Exchange | 74449F118 CUSIP |
| CA Country | 12 Employees | - Last Dividend | - Last Split | 25 Jan 2024 IPO Date |
Overview
Psyence Biomedical Ltd. is a pioneering company that specializes in the development of botanical psilocybin-based psychedelic medicines, with a focus on addressing mental health conditions and improving quality of life for patients facing incurable cancer diagnoses in palliative care settings. Positioned at the forefront of psychedelic medicine, Psyence Biomedical Ltd. evaluates natural sources of psilocybin for their therapeutic potential. The company's efforts are aimed at offering novel treatment options for adjustment disorder and other psychological ailments that often accompany terminal illnesses. Operating under the umbrella of Psyence Group Inc., Psyence Biomedical is headquartered in Toronto, Canada and demonstrates a commitment to leveraging psilocybin's potential for mental health and palliative care interventions.
Products and Services
- PEX010
As the lead product candidate of Psyence Biomedical Ltd., PEX010 is currently in Phase IIb clinical studies. This product is a capsule containing naturally sourced psilocybin, designed for the treatment of a spectrum of conditions including anxiety, depression, post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially within the palliative care context. By advancing through critical research phases, PEX010 aims to revolutionize the approach to mental health care for patients undergoing severe emotional and psychological distress due to incurable illnesses.
- Partnership with iNGENu Pty Ltd
In collaboration with iNGENu Pty Ltd, Psyence Biomedical Ltd. is conducting a Phase IIb clinical trial utilizing PEX010 in psilocybin-assisted psychotherapy. This innovative trial targets Adjustment Disorder (AjD) triggered by the diagnosis of incurable cancer, exploring the benefits of combining traditional psychotherapy with psilocybin treatment to enhance patient coping mechanisms and overall wellbeing. Through this partnership, Psyence Biomedical seeks to underline the therapeutic value of psilocybin in supporting emotional and mental health in a highly vulnerable patient population.
